146 related articles for article (PubMed ID: 8821301)
1. Ultra rush bee venom immunotherapy does not reduce cutaneous weal responses to bee venom and codeine phosphate.
Jutel M; Skrbic D; Pichler WJ; Müller UR
Clin Exp Allergy; 1995 Dec; 25(12):1205-10. PubMed ID: 8821301
[TBL] [Abstract][Full Text] [Related]
2. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils.
Jutel M; Müller UR; Fricker M; Rihs S; Pichler WJ; Dahinden C
Clin Exp Allergy; 1996 Oct; 26(10):1112-8. PubMed ID: 8911695
[TBL] [Abstract][Full Text] [Related]
3. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures.
Jutel M; Pichler WJ; Skrbic D; Urwyler A; Dahinden C; Müller UR
J Immunol; 1995 Apr; 154(8):4187-94. PubMed ID: 7706753
[TBL] [Abstract][Full Text] [Related]
4. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
5. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy.
McHugh SM; Deighton J; Stewart AG; Lachmann PJ; Ewan PW
Clin Exp Allergy; 1995 Sep; 25(9):828-38. PubMed ID: 8564721
[TBL] [Abstract][Full Text] [Related]
6. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
7. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
8. Laboratory markers of mast cell and basophil activation in monitoring rush immunotherapy in bee venom-allergic children.
Cichocka-Jarosz E; Dorynska A; Pietrzyk JJ; Spiewak R
Immunotherapy; 2011 Aug; 3(8):1013-7. PubMed ID: 21843104
[TBL] [Abstract][Full Text] [Related]
9. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.
Bellinghausen I; Metz G; Enk AH; Christmann S; Knop J; Saloga J
Eur J Immunol; 1997 May; 27(5):1131-9. PubMed ID: 9174602
[TBL] [Abstract][Full Text] [Related]
10. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
11. Review of venom immunotherapy at a regional tertiary paediatric centre.
Johnston N; Belcher J; Preece K; Bhatia R
J Paediatr Child Health; 2022 Jul; 58(7):1228-1232. PubMed ID: 35416342
[TBL] [Abstract][Full Text] [Related]
12. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells in children undergoing rush venom immunotherapy.
Ajduk J; Turkalj M; Gagro A
Allergy Asthma Proc; 2012; 33(6):525-30. PubMed ID: 23394512
[TBL] [Abstract][Full Text] [Related]
14. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
[TBL] [Abstract][Full Text] [Related]
15. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
Goldberg A; Confino-Cohen R
Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
[TBL] [Abstract][Full Text] [Related]
16. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
17. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
[TBL] [Abstract][Full Text] [Related]
18. Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature.
Diwakar L; Noorani S; Huissoon AP; Frew AJ; Krishna MT
Clin Exp Allergy; 2008 Oct; 38(10):1651-8. PubMed ID: 18727621
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunological response in patients with venom allergy during specific immunotherapy.
Szymański W; Chyrek-Borowska S
Rocz Akad Med Bialymst; 1995; 40(2):376-82. PubMed ID: 8834621
[TBL] [Abstract][Full Text] [Related]
20. The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract.
Quercia O; Rafanelli S; Puccinelli P; Stefanini GF
J Investig Allergol Clin Immunol; 2001; 11(1):27-33. PubMed ID: 11436967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
